MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

883.96 -33.69 (-3.67%)
Official Closing Price Updated: 7:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
News headline image
S&P 500 to 7,800? Morgan Stanley Bets on "One Big Beautiful Act" and AI Productivity as Bears Warn of Bubble
As the first quarter of 2026 unfolds, the equity markets are at a historic crossroads. Morgan Stanley (NYSE:MS) has stunned Wall Street with a revised year-end target for the S&P 500, projecting the... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Eli Lilly Unusual Options Activity For March 04 ↗
 
Via Benzinga
News headline image
Is Moderna Stock Outperforming the Dow?
Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects. 
Via Barchart.com
Topics Stocks
Eli Lilly & Co (NYSE:LLY): A High-Growth Dividend Stock for Discerning Investors ↗
Via Chartmill
News headline image
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last ↗
The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro. 
Via Stocktwits
Topics Lawsuit
News headline image
2 Top Growth Stocks to Buy in the First Half of 2026 ↗
A decade from now, you might be very glad you did so. 
Via The Motley Fool
News headline image
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Best Healthcare Stock to Invest $1,000 in Right Now ↗
There's nothing generic about this drugmaker's recent performance and continued prospects. 
Via The Motley Fool
News headline image
Buying This 1 Pharmaceutical Stock Today Could Make You a Multimillionaire Retiree ↗
This stock looks unstoppable right now. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Why I'm Not Worried About Novo Nordisk Stock ↗
The stock is down big of late, but the business is by no means doomed. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock? ↗
Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way. 
Via The Motley Fool
News headline image
Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead? ↗
Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials
The final trading week of February 2026 has laid bare a striking fracture in the U.S. equity markets. While the technology sector continues to feast on a relentless AI-driven "execution" cycle, the... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The 7,800 Frontier: Morgan Stanley Flips the Script with Bullish S&P 500 Forecast
In a dramatic departure from his historically cautious stance, Mike Wilson, Chief U.S. Equity Strategist at Morgan Stanley (NYSE: MS), has stunned Wall Street by raising the firm’s 12-month S&P 500... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional... 
Via MarketMinute
Topics Artificial Intelligence ETFs
News headline image
S&P 500 Crosses Historic 7,000 Milestone: Technical and Psychological Significance of the Breakout
In a defining moment for global financial markets, the S&P 500 Index officially breached the 7,000-point mark for the first time in history on January 28, 2026. This monumental achievement underscores... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?
Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects. 
Via Barchart.com
Topics Stocks
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
OPKO Health (OPK) Q4 2025 Earnings Call Transcript ↗
OPKO Health (OPK) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
The Great Recalibration: Investors Pivot from Silicon Dreams to Industrial Reality
As the bull market of the mid-2020s enters a more mature and discerning phase, a profound shift is unfolding across global trading floors. The speculative fervor that once propelled "AI darlings" to... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
News headline image
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
The maker of Wegovy hasn't said its last words just yet. 
Via The Motley Fool
News headline image
Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗
The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures. 
Via The Motley Fool
News headline image
Viking Therapeutics: The High-Stakes Weight Loss Contender ↗
Via MarketBeat
News headline image
Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 ↗
Eli Lilly shares rise after orforglipron beats Novo's drug in Phase 3, cutting A1C by 2.2% and boosting weight loss results. 
Via Benzinga
News headline image
The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier
As the final week of February 2026 draws to a close, the financial markets have emerged from what analysts are calling the most consequential “Heavyweight Week” of the post-pandemic era. The... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026
As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Alphabet Inc. (GOOGL) Deep Dive: Navigating the Agentic Era and the $180 Billion AI Bet
As of February 26, 2026, Alphabet Inc. (NASDAQ: GOOGL) stands at a defining crossroads in its nearly three-decade history. Long the undisputed gatekeeper of the internet’s information, the Mountain... 
Via Finterra
Topics Artificial Intelligence Initial Public Offering Workforce
News headline image
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗
How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think. 
Via The Motley Fool
News headline image
Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial ↗
Investors are closely watching the oral GLP-1 race as competition intensifies across the sector. 
Via Stocktwits
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story